

| Drug Utilization Review Board Meeting | | | |
|---|---|--------------------|---------------|
| December 13, 2016 | | | |
| Therapeutic Class | Drug Name | Current PDL Status | DCH Decisions |
| Drug Reviews | | | |
| Antivirals, Hepatitis C | | | |
| | Epclusa (Oral) Tablet | P/PA | P/PA |
| | Pegasys (Subcutaneous) Syringe/Autoinjector/ Solution | P | P |
| Parkinson's Disease Psychosis Agents | | | |
| | Nuplazid (Oral) Tablet | Non-PDL | NP/PA |
| Biologic Immunomodulators, Antipsoriatics | | | |
| | Taltz (Subcutaneous) Syringe/Autoinjector | Non-PDL | NP/PA |

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization